Cargando…
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Autores principales: | Alderuccio, Juan P., Ai, Weiyun Z., Radford, John, Solh, Melhem, Ardeshna, Kirit M., Lunning, Matthew A., Hess, Brian T., Zinzani, Pier L., Stathis, Anastasios, Carlo-Stella, Carmelo, Hamadani, Mehdi, Kahl, Brad S., Ungar, David, Kilavuz, Turk, Yu, Eric, Qin, Yajuan, Caimi, Paolo F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631657/ https://www.ncbi.nlm.nih.gov/pubmed/35790100 http://dx.doi.org/10.1182/bloodadvances.2022007782 |
Ejemplares similares
-
P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Caimi, Paolo F, et al.
Publicado: (2023) -
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022) -
P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
por: Spira, A., et al.
Publicado: (2022) -
PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022) -
PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)
por: Westin, J., et al.
Publicado: (2022)